ジーエヌアイグループの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/03/13 | 1,036 | 1,041 | 1,013 | 1,037 | -24 | -2.3% | 852,900 |
| 2023/03/10 | 1,055 | 1,070 | 1,042 | 1,061 | +9 | +0.9% | 602,200 |
| 2023/03/09 | 1,027 | 1,055 | 1,020 | 1,052 | +20 | +1.9% | 451,900 |
| 2023/03/08 | 1,049 | 1,050 | 1,029 | 1,032 | -24 | -2.3% | 638,200 |
| 2023/03/07 | 1,060 | 1,068 | 1,047 | 1,056 | -9 | -0.8% | 387,100 |
| 2023/03/06 | 1,079 | 1,084 | 1,065 | 1,065 | -1 | -0.1% | 244,800 |
| 2023/03/03 | 1,061 | 1,083 | 1,058 | 1,066 | +3 | +0.3% | 305,200 |
| 2023/03/02 | 1,055 | 1,069 | 1,044 | 1,063 | +13 | +1.2% | 436,300 |
| 2023/03/01 | 1,087 | 1,089 | 1,042 | 1,050 | -28 | -2.6% | 689,800 |
| 2023/02/28 | 1,068 | 1,097 | 1,068 | 1,078 | +14 | +1.3% | 586,700 |
| 2023/02/27 | 1,079 | 1,088 | 1,056 | 1,064 | -33 | -3% | 720,300 |
| 2023/02/24 | 1,115 | 1,117 | 1,093 | 1,097 | -9 | -0.8% | 288,200 |
| 2023/02/22 | 1,111 | 1,121 | 1,094 | 1,106 | -34 | -3% | 518,400 |
| 2023/02/21 | 1,155 | 1,155 | 1,130 | 1,140 | -14 | -1.2% | 326,200 |
| 2023/02/20 | 1,097 | 1,154 | 1,096 | 1,154 | +57 | +5.2% | 560,900 |
| 2023/02/17 | 1,117 | 1,140 | 1,090 | 1,097 | -31 | -2.7% | 759,500 |
| 2023/02/16 | 1,165 | 1,165 | 1,085 | 1,128 | -34 | -2.9% | 1,750,600 |
| 2023/02/15 | 1,167 | 1,169 | 1,135 | 1,162 | -11 | -0.9% | 734,300 |
| 2023/02/14 | 1,168 | 1,184 | 1,162 | 1,173 | +4 | +0.3% | 369,300 |
| 2023/02/13 | 1,166 | 1,174 | 1,147 | 1,169 | -3 | -0.3% | 324,800 |
| 2023/02/10 | 1,196 | 1,206 | 1,165 | 1,172 | -34 | -2.8% | 597,400 |
| 2023/02/09 | 1,195 | 1,208 | 1,192 | 1,206 | -3 | -0.2% | 340,500 |
| 2023/02/08 | 1,197 | 1,209 | 1,188 | 1,209 | +1 | +0.1% | 257,600 |
| 2023/02/07 | 1,208 | 1,213 | 1,198 | 1,208 | +8 | +0.7% | 229,900 |
| 2023/02/06 | 1,225 | 1,229 | 1,196 | 1,200 | -27 | -2.2% | 447,000 |
| 2023/02/03 | 1,231 | 1,243 | 1,220 | 1,227 | +9 | +0.7% | 280,800 |
| 2023/02/02 | 1,232 | 1,242 | 1,215 | 1,218 | +7 | +0.6% | 379,200 |
| 2023/02/01 | 1,202 | 1,242 | 1,197 | 1,211 | +18 | +1.5% | 415,300 |
| 2023/01/31 | 1,179 | 1,198 | 1,173 | 1,193 | -2 | -0.2% | 285,800 |
| 2023/01/30 | 1,222 | 1,233 | 1,185 | 1,195 | -20 | -1.6% | 432,800 |
| 2023/01/27 | 1,221 | 1,226 | 1,199 | 1,215 | +1 | +0.1% | 357,000 |
| 2023/01/26 | 1,238 | 1,249 | 1,210 | 1,214 | -15 | -1.2% | 319,300 |
| 2023/01/25 | 1,229 | 1,238 | 1,214 | 1,229 | -3 | -0.2% | 284,000 |
| 2023/01/24 | 1,243 | 1,246 | 1,219 | 1,232 | +8 | +0.7% | 341,400 |
| 2023/01/23 | 1,208 | 1,243 | 1,207 | 1,224 | +29 | +2.4% | 542,300 |
| 2023/01/20 | 1,213 | 1,218 | 1,182 | 1,195 | -31 | -2.5% | 517,600 |
| 2023/01/19 | 1,172 | 1,236 | 1,164 | 1,226 | +42 | +3.5% | 842,100 |
| 2023/01/18 | 1,137 | 1,197 | 1,134 | 1,184 | +54 | +4.8% | 855,400 |
| 2023/01/17 | 1,180 | 1,211 | 1,130 | 1,130 | -49 | -4.2% | 991,400 |
| 2023/01/16 | 1,199 | 1,219 | 1,175 | 1,179 | -35 | -2.9% | 680,800 |
| 2023/01/13 | 1,232 | 1,252 | 1,205 | 1,214 | -30 | -2.4% | 583,300 |
| 2023/01/12 | 1,254 | 1,261 | 1,208 | 1,244 | -9 | -0.7% | 669,900 |
| 2023/01/11 | 1,280 | 1,317 | 1,045 | 1,253 | -15 | -1.2% | 2,959,700 |
| 2023/01/10 | 1,307 | 1,319 | 1,265 | 1,268 | -29 | -2.2% | 427,000 |
| 2023/01/06 | 1,246 | 1,302 | 1,242 | 1,297 | +29 | +2.3% | 439,400 |
| 2023/01/05 | 1,288 | 1,303 | 1,266 | 1,268 | -10 | -0.8% | 514,700 |
| 2023/01/04 | 1,345 | 1,350 | 1,268 | 1,278 | -115 | -8.3% | 1,153,400 |
| 2022/12/30 | 1,351 | 1,418 | 1,324 | 1,393 | +49 | +3.6% | 1,208,600 |
| 2022/12/29 | 1,221 | 1,353 | 1,215 | 1,344 | +110 | +8.9% | 1,584,000 |
| 2022/12/28 | 1,331 | 1,331 | 1,213 | 1,234 | +23 | +1.9% | 2,261,600 |
301～
350
件表示中 / 3468件
類似銘柄と比較する
現在ご覧いただいている「ジーエヌアイ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ジーエヌアイ | 217,400円 | +52.1% | +23.3% | 0.00% | 15.39倍 | 3.21倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
| 杏林製薬 | 171,500円 | +3.2% | +4.5% | 3.03% | 19.71倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 鳥居薬 | 380,500円 | +7.3% | +16.8% | 3.15% | 22.76倍 | 0.89倍 |
|
ＪＴ傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗ＨＩＶ薬の販売権喪失が直撃 |
| ゼリア新薬 | 200,000円 | +9.6% | +17.5% | 2.30% | 11.30倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| 栄研化 | 208,100円 | +7.6% | +57.5% | 2.55% | 16.07倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割弱。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
